Dapagliflozin's influence on cardiac remodeling in chronic heart failure patients

11 May 2024 (08:00 - 20:00)

Organised by:

Sign in for access options

Sign in to view the resources

Sign in for access options

About the speaker

Doctor Ana Rita Ribeiro Teixeira

University Hospital Lisboa Central, Lisbon (Portugal)

4 More presentations in this session

Presentation thumbnail

Prognostic implications of adaptive and maladaptive right ventricular hypertrophy in patients with heart failure: a prospective observational cohort study

Doctor L. Dinc Asarcikli (Leiden, NL)

Abstract Slides Video

Presentation thumbnail

Predictors of early left ventricular reverse remodelling and prognosis in new-onset heart failure of non-ischemic origin

Doctor T. Hnat (Prague, CZ)

Abstract Slides Video

Presentation thumbnail

Cardiac reverse remodeling and SGLT2ii: insight from hemodynamic forces analysis

Doctor S. Prosperi (Rome, IT)

Abstract Slides Video

Presentation thumbnail

Safety and tolerability of diuretics withdrawal in heart failure with reduced ejection fraction. The REDICAE trial

Mr J. Torres Zamudio (Cordoba, ES)

Abstract Slides Video

Access the full session

Session thumbnail

Chronic heart failure - pathophysiology and mechanisms 7

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024

You may be interested in

Congress Presentation

Dapagliflozin effect on cardiopulmonary function, reverse cardiac remodelling and biomarkers in a cohort of HFrEF patients

Congress Presentation

Effects of Dapagliflozin on myocardial performance in non-diabetic patients with Heart failure with reduced and mid-range ejection fraction (DAPA ECHO trial)

Congress Presentation

Dapaglifozin in advanced heart failure patients : effects on congestion, NTproBNP and cardiorenal outcome

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources